PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities
Open Access
- 19 June 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1602752
Abstract
PLK1 plays a crucial role in cell cycle regulation and cancer development, and its dysregulation has been implicated in the prognosis of a variety of malignancies. The potential of PLK1 inhibitors as cancer therapeutics has been extensively investigated. However, the underlying biology and mechanisms of PLK1 remain incompletely understood. In recent years, numerous studies have demonstrated that PLK1 overexpression is associated with resistance to certain chemotherapeutic agents, while its inhibition can enhance the efficacy of chemotherapy. In addition, PLK1 inhibitors have been shown to selectively target cancer cells as radiation sensitizers and exert synergistic effects in combination immunotherapy. The underlying mechanisms may involve the regulation of multiple immune cells and inflammatory factors, as well as alterations in the tumor microenvironment, ultimately influencing tumor genesis, migration, and invasion. Moreover, PLK1 can regulate the expression of immune checkpoint-related proteins, thereby playing a synergistic role in cancer therapy. Furthermore, PLK1 represents a promising target antigen for cancer immunotherapy, with potential applications in optimizing cancer vaccines. Therefore, this review focuses on the applications and underlying mechanisms of PLK1 in tumor immunotherapy, aiming to provide new insights for improving patient outcomes and prognosis.Keywords
This publication has 136 references indexed in Scilit:
- Toosendanin promotes prostate cancer cell apoptosis, ferroptosis and M1 polarization via USP39-mediated PLK1 deubiquitinationNaunyn-Schmiedeberg's Archives of Pharmacology, 2025
- Balancing Plk1 activity levels: The secret of synchrony between the cell and the centrosome cycleBioEssays, 2024
- PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti‐tumor effectsMolecular Oncology, 2024
- Tangeretin attenuates acute lung injury in septic mice by inhibiting ROS-mediated NLRP3 inflammasome activation via regulating PLK1/AMPK/DRP1 signaling axisInflammation Research, 2023
- Performance of a PLK1‐based immune risk model for prognosis and treatment response prediction in breast cancerCancer Medicine, 2023
- Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal CancerAdvanced Science, 2021
- Regulating a key mitotic regulator, polo‐like kinase 1 (PLK1)Cytoskeleton, 2018
- Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cellsImmunologic Research, 2016
- Polo-Box Domain Inhibitor Poloxin Activates the Spindle Assembly Checkpoint and Inhibits Tumor Growth in VivoThe American Journal of Pathology, 2011
- Bladder cancer SNP panel predicts susceptibility and survivalHuman Genetics, 2009